vimarsana.com

Collaborative Network Of Networks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

APEIRON Biologics APN01 selected for large-scale US trial in COVID-19

APEIRON Biologics APN01 selected for large-scale US trial in COVID-19 DGAP-News: APEIRON Biologics AG / Key word(s): Study 19.05.2021 / 09:00 APEIRON Biologics APN01 selected for large-scale US trial  in COVID-19 APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development steps Vienna, Austria, 19 May 2021: APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery rou

APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19

APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19 APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development steps VIENNA, AUSTRIA / ACCESSWIRE / May 19, 2021 / APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery routes.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.